Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Completes KP415 Pre-NDA Meeting with FDA
KP415 NDA Filing Anticipated in Late Q2 or Early Q3 2019 Conference Call Scheduled for Today, Thursday, April 11, 2019 at 5:00 p.m. ET CELEBRATION, Fla. , April 11, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of
Toggle Summary KemPharm Provides Update on APADAZ® Formulary Adoption
Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted formulary access for 91% of Commercial lives and unrestricted access for 90% of state Medicaid lives According to MMIT
Toggle Summary KemPharm to Present at Upcoming Investor Conferences
CELEBRATION, Fla. , March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that management will present at several investor conferences during March 2019 .
Toggle Summary KemPharm Reports Q4 and FY 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse potential programs Received approval of APADAZ ® Enhanced pipeline with the addition of KP879, a potential new treatment
Toggle Summary KemPharm to Report Fourth Quarter and Year End 2018 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, February 28, 2019 , 4:30 p.m. ET CELEBRATION, Fla. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate
Patents Extend Across KemPharm’s Prodrug Portfolio, Including IP Protection for KP415 in Canada , Japan and Korea CELEBRATION, Fla. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting
Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” CELEBRATION, Fla. , Jan. 18, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)
APADAZ® Now Approved in Three Dosage Strengths, Providing Greater Flexibility to Prescribers Through Additional Dosing Options CORALVILLE, Iowa , Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio
CELEBRATION, Fla. , Dec. 19, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a corporate update on the ongoing partnering process for its co-lead clinical development product
Toggle Summary KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)
Findings suggest that SDX, a prodrug of d-methylphenidate, is unlikely to be attractive for intravenous abuse CELEBRATION, Fla. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,